{
  "id": 6273254,
  "title": "Inhibrx targets OX40 agonist-cancer vaccine studies from early next year",
  "url": "https://urgent.news/2026/09/08/inhibrx-targets-ox40-agonist-cancer-vaccine-studies-from-early-next",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T11:30:32.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/inhibrx-plots-ox40-agonist-cancer-vaccine-studies-from-early-next-year/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Inhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower immunogenicity. “The next step for ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}